The Journal of Rheumatology, Volume 8

THE EDITORS GRATEFULLY ACKNOWLEDGE THE GENEROUS ASSISTANCE OF THE FOLLOWING REVIEWERS DURING 1980-81

John Abruzzo
Mark Adams
Vincent Agnello
Kimmo Aho
Mahmoud Ali
Margaret Alspaugh
Roy Altman
Michael Ameli
Tassos Anastassiades
Barbara Ansell
J. R. Archer
Frank C. Arnett
Paul Bacon
Ronald Baigrie
John Bailey
Michael Baker
Fletcher Baragar
Colin Barnes
L. Barnes
Murray Baron
H. John Barrie
Reuben Baumal
Peter Bennett
Robert M. Bennett
Neil D. Berman
Bram Bernstein
William D. Biggar
Juan Bilbao
Duane Bishop
Gordon Blair
Laurence Blendis
Anthony Bohan
Claire Bombardier
Arthur Bookman
Norman Boyd
Walter Bradley
Kenneth Brandt
Calvin Breslin
Earl Brewer
Derek A. Brewerton
T. David Briant
Peter Brooks
Joseph Bruni
Thomas W. Bunch
Eric G. L. Bywaters
David Caldwell
Andrei Calin
Evan Calkins
Juan J. Canoso
Carl Cardella
Simon Carette
Peter Carlen
Dennis Carson
James Cassidy
C. William Castor
Edgar S. Cathcart
Abraham Chaiton
Andrew Chalmers
Ian Chalmers
William B. Chodirker
Charles Christian
Thomas Chused
Peter Clarke
Peter Cockshott
Alan S. Cohen
Barry Cole
Edward Cole
Philip Cole
Joseph Connon
Mary Corbett
John Crawhall
John Crocker
H. L. F. Curry
Charles Danby
Paul Davis
T. J. Daymond
Philippe de Bosset
John L. Decker
Earle DeCoteau
Charles W. Denko
Michael Denman
H. Roslyn Devlin
Nicholas Diamant
Herbert S. Diamond
Paul A. Dieppe
Alan St. J. Dixon
Carole Dorsch
Michael Dosch
Leith Douglas
Steven Douglas
D. C. Dumonde
Howard Duncan
Isaac Dwosh
R. W. Ebringer
Michael Ehrenfeld
Robert M. Ehrlich
George Ehrlich
John Esdaile
Luis Espinoza
Judy Falk
Adel Fam
A. S. Fauci
Ronald Feld
Benjamin Fisher
Denys Ford
Peter Ford
Victor Fornasier
Antonio Fraga
Arthur Franklin
Edward C. Franklin
George J. Friou
Marvin Fritzler
Lynn From
Brenda Gallie
Stephen Garnett
A. F. Geczy
Erwin Gelfand
Donald Gerber
Jean Gerster
Feroze Ghadially
James Gilliam
Dafna Gladman
Charles M. Godfrey
Donald Goldenberg
Charles Goldsmith
Armin E. Good
Norman Gottlieb
Anthony Graham
David Grayson
Floyd A. Green
Ira Green
Aubrey Groll
Harvey Grosman
Max Hamburger
Samuel Handelsman
Joe J. Hardin
Manfred Harth
Joan Harvey
Peter Hasselbacher
David E. Hastings
David Hawkins
Louis Healey
Jenny Heathcote
Antoine Helewa
Evelyn Hess
Joseph Hollander
David Horrobin
Joseph B. Houpt
John G. Humphrey
Gene Hunder

The Journal of Rheumatology, Volume 8

THE EDITORS GRATEFULLY ACKNOWLEDGE THE GENEROUS ASSISTANCE OF THE FOLLOWING REVIEWERS DURING 1980-81

John Abruzzo
Mark Adams
Vincent Agnello
Kimmo Aho
Mahmoud Ali
Margaret Alspaugh
Roy Altman
Michael Ameli
Tassos Anastassiades
Barbara Ansell
J. R. Archer
Frank C. Arnett
Paul Bacon
Ronald Baigrie
John Bailey
Michael Baker
Fletcher Baragar
Colin Barnes
L. Barnes
Murray Baron
H. John Barrie
Reuben Baumal
Peter Bennett
Robert M. Bennett
Neil D. Berman
Bram Bernstein
William D. Biggar
Juan Bilbao
Duane Bishop
Gordon Blair
Laurence Blendis
Anthony Bohan
Claire Bombardier
Arthur Bookman
Norman Boyd
Walter Bradley
Kenneth Brandt
Calvin Breslin
Earl Brewer
Derek A. Brewerton
T. David Briant
Peter Brooks
Joseph Bruni
Thomas W. Bunch
Eric G. L. Bywaters
David Caldwell
Andrei Calin
Evan Calkins
Juan J. Canoso
Carl Cardella
Simon Carette
Peter Carlen
Dennis Carson
James Cassidy
C. William Castor
Edgar S. Cathcart
Abraham Chaiton
Andrew Chalmers
Ian Chalmers
William B. Chodirker
Charles Christian
Thomas Chused
Peter Clarke
Peter Cockshott
Alan S. Cohen
Barry Cole
Edward Cole
Philip Cole
Joseph Connon
Mary Corbett
John Crawhall
John Crocker
H. L. F. Curry
Charles Danby
Paul Davis
T. J. Daymond
Philippe de Bosset
John L. Decker
Earle DeCoteau
Charles W. Denko
Michael Denman
H. Roslyn Devlin
Nicholas Diamant
Herbert S. Diamond
Paul A. Dieppe
Alan St. J. Dixon
Carole Dorsch
Michael Dosch
Leith Douglas
Steven Douglas
D. C. Dumonde
Howard Duncan
Isaac Dwosh
R. W. Ebringer
Michael Ehrenfeld
Robert M. Ehrlich
George Ehrlich
John Esdaile
Luis Espinoza
Judy Falk
Adel Fam
A. S. Fauci
Ronald Feld
Benjamin Fisher
Denys Ford
Peter Ford
Victor Fornasier
Antonio Fraga
Arthur Franklin
Edward C. Franklin
George J. Friou
Marvin Fritzler
Lynn From
Brenda Gallie
Stephen Garnett
A. F. Geczy
Erwin Gelfand
Donald Gerber
Jean Gerster
Feroze Ghadially
James Gilliam
Dafna Gladman
Charles M. Godfrey
Donald Goldenberg
Charles Goldsmith
Armin E. Good
Norman Gottlieb
Anthony Graham
David Grayson
Floyd A. Green
Ira Green
Aubrey Groll
Harvey Grosman
Max Hamburger
Samuel Handelsman
Joe J. Hardin
Manfred Harth
Joan Harvey
Peter Hasselbacher
David E. Hastings
David Hawkins
Louis Healey
Jenny Heathcote
Antoine Helewa
Evelyn Hess
Joseph Hollander
David Horrobin
Joseph B. Houpt
John G. Humphrey
Gene Hunder

G. W. Hunninghake
Thomas Hunter
Eric Hurd
Edward C. Huskisson
Robert Hyland
Robert Inman
Robert Irby
Robert Jackson
Ralph Jacox
Israeli Jaffe
D. T. Janigan
M. K. Jasani
C. G. M. Kallenberg
Morton Kapusta
Arthur Karasik
Jacob Karsh
Allan Katz
Walter Kean
John Kelton
Alastair Kennedy
Muhammad A. Khan
Donald W. Killinger
T. Douglas Kinsella
William Kirkaldy-Willis
Robert Kisilevsky
Pirrko Kiviniemi
Michel Klein
James Klinenberg
Barry E. Koehler
Franklin Kozin
Gunnar Kraag
Henry Kunkel
Irving Kushner
Frans Leenan
Frances Leung
Raymond Lewkonia
Arthur Leznoff
J. T. Lie
Peter Lipsky
Irving Lipton
A. Hugh Little
J. Alick Little
Geoffrey O. Littlejohn
Allen MacKenzie
Stuart M. MacLeod
Peter Maddison
William Mahon
Stephen E. Malawista
Neil Mandel
Joseph Markenson
Joanne Marsh
Glenn McCain
Daniel J. McCarty
Alan McComas
Brian McConkey
William McIlroy
Robert McKendry
David McNeely
Robert S. Meenan
Ronald Messner
H. Mielants
William Mikkelsen
Stephen Milazzo
John Miller, III
Marion Miller
Joseph Minta
Gregorio Mintz
Donald Mitchell
Harvey Moldofsky
John Moll
Mary E. Moore
Thomas Muckle
Helen Muir
Allen Myers
Jacob Natvig
David Newcombe
Michael Newhouse
William O'Brien
J. Desmond O'Duffy
Pearaylal Ogra
Elliot Osserman
Gabriel Panayi
Richard Panush
Frixos Paraskevas
W. M. Park
Thomas Paton
Harold E. Paulus
John S. Percy
Robert Persellin
Donald Person
Ross E. Petty
Paul Phillips
Robert Pinals
Paul H. Plotz
Howard Polley
A. J. Poole
Richard M. Pope
Barry Posner
Kathleen Pritchard
Kenneth Pritzker
Ed Prokipchuk
Thomas Provost
Ian Quirt
Colin Ramsey
Joyce Rauch
Morris Reichlin
Graham Reid
W. John Reynolds
David Rimoin
Richard Riopelle
Harold S. Robinson
Gerald P. Rodnan
Daniel Roncari
Patrick Rooney
James Rosenbaum
Donald Rosenthal
Leonard Rosenthall
Naomi Rothfield
Joel Rubenstein
Shaun Ruddy
Lorne Runge
M. Lynn Russell
Eugene St. Louis
Jane Schaller
Joseph Schatzker
Morton Scheinberg
Thomas Schnitzer
Peter Schur
Gordon C. Sharp
Abraham Shore
Rhonda Shuckett
Marc Shulman
Kenneth Shumak
Charles Sienknecht
Albert Silverman
Kathy Siminovitch
Peter A. Simkin
Nancy Simpson
Martha Skinner
Carol Smith
Leon Sokoloff
Nicholas Soter
William Spaulding
Walter O. Spitzer
Peter Stastny
Allen Steere
Howard Stein
Alfred D. Steinberg
Joel Steinberg
George Steiner
John D. Stobo
Roger Sturrock
Michael Sugai
Stephen Sullivan
David Sutton
Arne Svejgaard
Robert Swezey
David Swinson
Norman Talal
Eng Tan
Hyman Tannenbaum
Jerry Tenenbaum
Marius Teodorescu
Carter Thorne
Marvin Tile
Alexander Townes
Elaine Tozman
David Trentham

Peter Tugwell
Robert Turner
Peter R. Uldall
Peter D. Utsinger
Carel Van Oss
W. Van Wyck
Stephen Vas
Hillar Vellend
Barrie Vernon-Roberts
Eric M. Veys
Paul Vignos
Thomas Waldman
John Walshe
Ian Wanless
John Ward
John Webb
Michael Webley
Herbert Weiner
Michael Weintraub
Peter Welsh
Keith Whaley
John Wherret
John Whitaker
Theresa Whiteside
Sharon Wilkinson
Ralph C. Williams
Robert Willkens
John Winfield
Richard Winkelman
Philip Wood
Edmund R. Yendt
David Yu
Robert Zurier

NIH CONSENSUS DEVELOPMENT CONFERENCE
ON TOTAL HIP JOINT REPLACEMENT

MARCH 1 - 3, 1982
Masur Auditorium, Building 10, National Institutes of Health
Bethesda, Maryland

Sponsored by the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases with assistance from the NIH Office for Medical Applications of Research.

Write: DR. STEPHEN L. GORDON,
Director, Musculoskeletal Diseases Program,
National Institute of Arthritis, Diabetes,
and Digestive and Kidney Diseases,
Westwood Building, Room 405,
Bethesda, MD 20205,
(301) 496-7326

The Journal of Rheumatology Volume 8

AUTHOR INDEX

Pages 1-1029 and Supplement 7, 1981

A

Abdou NI, 9
Abeles M, 405
Abuaf N, (suppl 80)
Adams A, *(abstr)* 1,018
Adams, LE, 587
Adams ME, *(abstr)* 1,015
Agudelo CA, 69
Ahern MJ, 767
Akaoka I, 563
Alarcon GS, 621
Alarcon-Segovia D, *(letter)* 174, 291, 325, 509, *(editorial)* 535, 808
Alexander EL, 398
Ali SY, *(abstr)* 1,011
Allen C, 433
Amaki I, 19
Anderson B, 204
Andrews BS, 311
Andrews, R, 889
Ansell BM, (suppl 112, 124), 321
Aoba T, *(abstr)* 1,010
Appelboom T, *(letter)* 528, 643
Arend WP, 679
Arlot M, 440, 447
Arnett FC, 398, 797, 925
Arnold PI, *(letter)* 697
Arrigoni-Martelli E, (suppl 62)
Arturi AS, *(abstr)* 1,010
Atdjian M, 989
Austin T, 100
Awerbuch MS, 423

B

Bacon PA, 433
Baghat N, *(abstr)* 1,016
Ballou SP, 308
Banim SE, *(letter)* 516
Bankhurst AD, *(letter)* 175
Barnett EV, 258, 456, 804, 825
Baron A, *(letter)* 174
Baron M, 477, 747
Barrie HJ, 246
Bashir HV, *(letter)* 1,023
Baud CA, *(abstr)* 1,007
Baum J, *(letter)* 171, *(book review)* 532
Bayliss M, *(abstr)* 1,016
Belin DC, 331
Bell DA, 100, 340, 416, 486
Ben-Aryeh H, *(letter)* 354
Bennett RM, *(letter)* 518
Bergert JH, *(abstr)* 1,005
Bergevin H, (suppl 175)
Bessent RG, *(letter)* 694
Betts F, *(abstr)* 1,009
Bhogal RS, *(letter)* 519
Bias WB, 398, 797, 925
Binderup L, (suppl 62)
Birnbaum JE, (suppl 84)
Bjelle A, 110, 959
Blaker RG, 258
Blechman Wj, 949
Blodgett RC, 317
Bluhm T, *(abstr)* 1,012
Bocanegra TS, 621, *(letter)* 1,026
Boivin G, *(abstr)* 1,007
Boles JM, *(letter)* 174
Bombardier C, *(editorial)* 873
Bookman AAM, *(book review)* 702
Boone JE, *(book review)* 1,028
Bortolotti N, *(letter)* 179
Boskey AL, *(abstr)* 1,007, *(abstr)* 1,009
Bossingham DH, *(letter)* 172
Bothamley JE, 433
Boyd RE, 311
Boyden KN, 547
Braun WE, 295
Bravo MG, 291
Brewer EJ, 138
Bridgeford PH, *(letter)* 869
Brooks RG, 937
Brown MG, 937
Brown NL, 955
Brown WE, *(abstr)* 1,008
Buchanan WW, *(book review)* 701
Buelens H, 45
Bulay O, *(abstr)* 1,009
Bumbier EE, 829
Burdash NM, 837
Buys WCAM, 31
Byrd WE, *(letter)* 698
Bywaters EGL, *(letter)* 175

C

Calamia KT, 993
Calin A, 969, *(letter)* 1,025
Calvert PD, *(abstr)* 1,014
Camp AV, (suppl 103, 124, 164)
Camus J-P, (suppl 80, 124, 175)
Cane D, 747
Canoso JJ, 974
Capell HA, 730
Carlson GL, (suppl 51)
Carrano j, (suppl 56, 169)
Carrillo C, 621
Cassell S, 825
Catalano JD, 141
Chamberlain Mj, 486
Chanzy H, *(abstr)* 1,012
Cheah PS, *(letter)* 1,025
Cheng P-T, 273, 451, 772, *(abstr)* 1,004, *(abstr)* 1,006, *(abstr)* 1,015
Cheroutre L, 45
Chia D, 258, 456, 804
Chodirker WB, *(letter)* 695
Christiansen FT, *(letter)* 1,025
Christoffersen J, *(abstr)* 1,017
Christoffersen MR, *(abstr)* 1,017
Ciosek CP Jr, 367
Cleland LG, 767, 841
Coates JE, 490
Cohen AS, 760
Cohen P, *(letter)* 692
Cohen TB, *(letter)* 1,021
Colman GH, *(abstr)* 1,016
Conn DL, 902
Cowan DH, 845
Crawhall JC, (suppl 20, 100, 161)
Crocker PR, *(abstr)* 1,017
Cros D, 336
Crouzet J, (suppl 80, 175)
Cyna J, 820
Cywiner-Golenzer C, 820

D

Daculsi G, *(abstr)* 1,007
Dancey JT, 679
Danehower RL, (suppl 124)
da Roza DM, 220
Davis DE, 317, 833, *(letter)* 866
Davis P, *(editorial)* 364, 490
Dawkins RL, (suppl 56, 124, 169), *(letter)* 1,025
de Benyacar MAR, *(abstr)* 1,010
de Bernard B, *(letter)* 179
Deganello S, *(abstr)* 1,006
de Groot ER, 880
Delcambre B, *(letter)* 521
del Giudice-Knipping JA, 325
Delrieu F, (suppl 80)
Deslandes Y, *(abstr)* 1,012

Deyo RA, 931
Dhondt E, 45
Dickson ER, (suppl 51, 121, 124)
Dieppe PA, *(abstr)* 1,014, *(abstr)* 1,016
DiMartino MJ, 829
Disney TF, 100
Dix D, *(letter)* 692
Dixon AStJ, *(editorial)* 361
Dlesk A, 129
Dormandy TL, 233
Dorner RW, 811
Dostal C, *(letter)* 864
Doyle DV, *(letter)* 516
Dryll A, 820
Dubler E, *(abstr)* 1,012
DuQuesnoy B, *(letter)* 521

E

Early CB, *(letter)* 700
Eckels DD, 214
Edelman J, 482
Edmonds JP, *(letter)* 1,023
Ehrenfeld M, 851
Eiken O, 856
Elliott JC, *(abstr)* 1,020
Ellman MH, 632, 955
Elson CJ, 433
Elveback LR, 993
Engleman EP, *(editorial)* 705
Espinoza LR, 621, *(letter)* 869, *(letter)* 1,026

F

Fam AG, 273, 281, *(letter)* 349, 845, *(letter)* 861, *(letter)* 867, *(book review)* 1,029
Famaey J-P, *(letter)* 181, *(letter)* 528, 643
Faure G, 512, *(abstr)* 1,007, *(abstr)* 1,016
Featherstone JDB, *(abstr)* 1,008
Ferguson RH, 902
Fernandez-Madrid F, 989
Ferry GD, 138
Fiddis RW, *(abstr)* 1,014
Fischel R, 851
Fischman AS, 405
Fisher M, (suppl 149)
Ford DK, 220
Forster TJ, 653
Fraga A, 325
Franklin GW, 501
Frayha RA, 670
Friis J, *(editorial)* 541
Fujimori S, 563

G

Gamby T, 336
Garcia-Morteo O, *(abstr)* 1,010
Garlepp MJ, (suppl 56, 169)
Garre M, *(letter)* 174
Gatenby PA, 504
Gaucher A, 512, *(abstr)* 1,007, *(abstr)* 1,016
Gaylis NB, 145
Geczy AF, *(letter)* 1,023
Germain BF, 621, *(letter)* 869, *(letter)* 1,026
Gershwin ME, 214
Gertzbein SD, 281
Gibson T, 752
Gladman DD, 741, 747
Glick JH, 69
Go VLW, (suppl 51)
Goethals L, 45
Gofton JP, *(letter)* 1,025
Goldhar JNH, 983
Goldin DS, 974
Goldlust MB, 367
Goldman JA, *(editorial)* 707
Gomez-Reino JJ, *(letter)* 529
Gonano F, *(letter)* 179
Gordon DA, *(editorial)* 4, (suppl 124), 303, *(letter)* 695
Gordon PA, 490
Gorevic PD, *(letter)* 529
Gottlieb NL, 145, *(letter)* 697
Gotuzzo E, 621
Grant KD, 587
Gray RG, 145
Greenwald RA, (suppl 9, 124), *(editorial)* 185
Gregory SA, 494
Grennan DM, 266
Gribnau FWJ, 639
Griffiths MM, 647
Griswold DE, 829
Gross AE, 983
Gruson M, 193
Grynpas MD, *(abstr)* 1,019
Guerra J Jr, 161
Guilland-Cumming DF, *(abstr)* 1,015

H

Ha'eri GB, 149
Hahn BH, 783
Hahn JL, 555
Hale GM, 266
Hall MA, (suppl 112)
Halloran SP, 233
Hana I, *(letter)* 864
Harrington TM, 833
Harris ED Jr, 555
Harth M, 100, 486
Harvey J, 797
Hashimoto A, 563
Hassanein KM, 9
Hasselbacher P, 57, 555, *(letter)* 697, *(abstr)* 1,013
Hastings DE, *(book review)* 871
Hazleman BL, 125
Heap P, *(abstr)* 1,016
Hearn PR, *(abstr)* 1,015
Heinicke M, *(letter)* 529
Henderson DRF, 423, 767
Henderson JM, 486
Hendrickson SM, 547
Hepburn B, 635
Hess EV, 587
Hibrawi H, 258
Higgins MJ, *(letter)* 700
Hinostroza S, 621
Hirai G, *(abstr)* 1,018
Hirai H, 19
Hirsch TJ, 925
Hogan DB, 673
Homberg J-C, (suppl 80)
Horiuchi Y, 563
Hoshi K, 299
Houpt JB, 983
Hsu SH, 797
Hughes GRV, *(letter)* 350, 605
Humphrey JG, 303
Hunder GG, 993
Hunninghake LH, (suppl 124)
Hunt RE, *(letter)* 698
Hunter JA, 730
Hunter T, *(book review)* 1,027
Hurd ER, 581
Hurley JA, *(book review)* 359
Husain Z, *(letter)* 176
Huskisson EC, (suppl 124, 146, 180), *(letter)* 516
Hyla JA, *(letter)* 176

I

Iczkovitz JM, 157
Inui TS, 931
Irby WR, 661
Irvin WS, *(letter)* 355
Isenberg DA, 599, 917
Itzkowitch DF, *(letter)* 528
Ivaskova E, *(letter)* 864
Iwaki Y, 804

J

Jabbs JM, *(letter)* 176
Jaffe I, (suppl 27, 124)
Jellum E, (suppl 14)
Jones JG, 125
Jouquan J, *(letter)* 174

K

Kallen PS, *(letter)* 526
Kamatani N, 563
Kampf AR, *(abstr)* 1,006
Kaplan S, 91
Kaprove RE, 791
Karp GI, 685
Kaslow RA, 969
Kåss E, (suppl 14, 107)
Kaye RL, 969
Kelley MA, *(letter)* 1,021
Kennedy AC, *(letter)* 694
Kerebel B, *(abstr)* 1,007
Kerwar SS, (suppl 84)
Keystone EC, *(book review)* 183, 665, 747, *(book review)* 872
Khan MA, 86, 295, 308
Khan MK, 86
King P, *(letter)* 1,026
Kinsella TD, 153
Kirwan P, 504
Klee WA, *(abstr)* 1,008
Klein M, *(editorial)* 188
Kobayashi K, 40
Koehler BE, 119
Koehler MG, 119
Korn JH, 501
Kozin F, 91, *(abstr)* 1,013
Kucharczyk N, (suppl 28)
Kushner I, 86, 295

L

Lagier R, *(abstr)* 1,007
Lamers MC, 880
Lane JM, *(abstr)* 1,009
Lang AE, 303
Langer AM, *(abstr)* 1,018
Latman NS, 725
Lauer CS, 504
Lava NS, *(letter)* 523
Lavalle C, 325
Lea DJ, 390
Lecavalier DR, (suppl 20)
LeClercq SM, 490
Lee P, *(editorial)* 6, *(book review)* 701, *(book review)* 871
Lee VW, 760
Leek JC, 157, 653
Leib ES, 258
LeMenn G, *(letter)* 868
Lemmer JP, 661
Leonello PP, 841
Lester R, *(letter)* 349
Levinson AI, *(letter)* 1,021
Levison DA, *(abstr)* 1,017
Levo Y, 851
Lewis AJ, 845
Lewkonia RM, 153
Lichtenstein JR, 79
Lindsley HB, 9
Lindstrom CG, 856
Lipsky PE, (suppl 69, 124)
Little AH, *(book review)* 183, 273, 416
Littlejohn GO, 665, 965
Loadholt CB, 837
Louie JS, *(letter)* 526
Lovy MR, *(letter)* 350, 605
Lunec J, 233
Lust G, *(abstr)* 1,016
Luthra HS, 902
Lyle WH, (suppl 96, 124)
Lynch CJ, *(letter)* 352

M

Macurova H, *(letter)* 864
Magi M, 110
Maitland A, 149
Makarowski WS, 626
Maldonado-Cocco JA, *(abstr)* 1,010
Mandel G, *(abstr)* 1,004, *(abstr)* 1,013
Mandel N, 955, *(abstr)* 1,004, *(abstr)* 1,013
Manicourt DH, 613
Marchessault RH, *(abstr)* 1,012
Marcos JC, *(abstr)* 1,010
Marino CT, *(letter)* 866
Marsh JM, 710, 937
Martincic RR, 204
Maryon EB, 647
Marzluff JM, *(letter)* 700
Massias P, (suppl 80)
Mastaglia GL, 658
Matalon JR, *(abstr)* 1,010
Mathew M, *(abstr)* 1,008
McCain GA, 100
McCarty DJ, *(letter)* 353, *(abstr)* 1,019
McDonald BL, (suppl 56, 169)
McGuire MB, *(abstr)* 1,015, *(abstr)* 1,016
McKendry RJR, 673
McPhaul LW, (suppl 51)
McMillan RM, 555
Medof ME, 632
Meed SD, 689
Mehra R, 141
Melo-Gomes E, 462
Melo-Gomes JA, 462
Menchions B, *(editorial)* 873
Mery C, (suppl 80)
Meyer O, 820
Mielants H, 45
Milazzo SC, 423, 767
Miller JJ III, 716
Miller OF, 317
Millman RP, *(letter)* 1,021
Milne JR, *(letter)* 516
Minta JO, 741
Mitrovic DR, 193
Mizushima Y, 40, 299
Molina J, 69
Mooradian A, 671
Moore M, *(abstr)* 1,011
Moore PB, *(abstr)* 1,006
Moore SB, 993
Moore TL, 79, 141, 811
Moorhead JF, *(abstr)* 1,011
Moran JJ, 833
Morgan GJ Jr, 979
Mori M, 40
Morita K, 19
Morling N, *(editorial)* 541
Moro L, *(letter)* 179
Morrow WJW, 599
Morse E, 331
Motta A, *(letter)* 179
Mottier D, *(letter)* 868
Mowat AG, 575
Mowat AM, 575
Mueller MN, *(letter)* 862
Muirden KD, 547
Muniain M, 783
Munthe E, (suppl 14, 107)
Murdoch RM, 730
Myers AR, 62, 752

N

Nahir AM, *(letter)* 354
Nakata S, 804
Nancollas GH, *(abstr)* 1,014
Netter P, 512, *(abstr)* 1,007, *(abstr)* 1,016
Neucks SH, 141, 811
Nickeson RW, 138
Nies KM, *(letter)* 526
Nishida Y, 563
Nishikai M, 925
Nishinarita S, 19
Nobunaga M, 910
Norman JE, 841
Nyburg SC, 451, *(abstr)* 1,015

O

Ochi T, 895
Oldershaw MD, *(abstr)* 1,008
Olds-Arroyo L, 716
Omar SA, 281, 451
Ono K, 895
Orloff S, 613

Oronsky AL, (suppl 84)
Osborn TG, 79
Osterland CK, *(book review)* 532
Owen ET, 482, 658, *(letter)* 1,025

P

Pachman L, 632
Palferman TG, *(letter)* 169
Palmer DG, 266
Panush RS, 129
Park JR, 125
Park MS, 804
Parry HF, 599
Pascual E, 9
Passero FC, 62
Pennec Y, *(letter)* 868
Percy JS, *(editorial)* 364, *(editorial)* 878
Perrett D, (suppl 41)
Peskett SA, 321
Phelps P, 889
Phillips PE, 344
Pinals RS, 815, 949
Planas-Bohne F, (suppl 35)
Platts-Mills AE, 321
Pletscher LS, 783
Plymate SR, 498
Podewell C, 501
Pollock M, 266
Ponzio AD, 837
Pooley FD, *(abstr)* 1,018
Poplonski L, 747
Poppo MJ, 145
Prier A, (suppl 175)
Pritzker KPH, 273, 281, 451, *(book review)* 532, 772, 983, *(introduction)* 1,000, *(abstr)* 1,004, *(abstr)* 1,006, *(abstr)* 1,015
Pruzanski W, (suppl 1), 477

R

Racela LS, 9
Ralph E, 100
Reichlin M, 925
Reid GD, *(letter)* 695
Reisner I, *(abstr)* 1,008
Rennie JAN, 730
Resnick D, 161
Reynolds PMG, *(letter)* 694
Richards AJ, *(letter)* 182, *(book review)* 184
Roback DW, 710
Robbins DL, 157, 653, 811
Robertson F, 949
Robinson AD, 547
Rodgers AL, *(abstr)* 1,005
Rodnan GP, (suppl 116, 124), *(letter)* 352
Rodriguez de la Serna A, 808
Rogers WW, 494
Roncaglia L, *(letter)* 179
Roos D, 880
Rosenbaum J, 969
Rosenbloom J, 889
Rosner SM, *(letter)* 519
Ross GT, 710
Rothfield NF, 405
Rothwell RS, 490
Runge LA, *(letter)* 176, 468
Russell AS, 347, *(editorial)* 364, 490, *(letter)* 1,025
Russell RGG, *(abstr)* 1,015, *(abstr)* 1,016
Ryan PFJ, 605
Ryckewaert A, 193, 820
Ryder LP, *(editorial)* 541

S

Sachs ML, *(letter)* 1,021
Sakae T, *(abstr)* 1,018
Sakai K, 910
Scharf Y, *(letter)* 354
Scheinberg IH, (suppl 90, 124, 149, 178)
Schenfeld L, 145
Schlegelmilch JG, 979
Schonborner A, *(abstr)* 1,007
Schultz DR, *(letter)* 697
Schumacher HR, 69, 380
Schwartz HA, 952
Schweiger F, 416
Scott DGI, 433
Searles RP, 498
Seegmiller JE, *(abstr)* 1,016
Seibold JR, *(letter)* 352
Sencer H, *(abstr)* 1,009, *(abstr)* 1,010
Sencer O, *(abstr)* 1,009, *(abstr)* 1,010
Serratrice G, 336
Shah JS, *(abstr)* 1,016
Shah P, 220
Shahinian S, (suppl 28)
Shapiro D, *(letter)* 354
Shearn MA, *(letter)* 522
Sheeler LR, 626
Sheppeard H, 390
Shields CP, *(abstr)* 1,008
Shingu M, 581, 910
Shoji Y, 299
Shupak R, 477
Siame JL, *(letter)* 521
Siminovitch K, *(editorial)* 188
Simkin PA, *(letter)* 693
Simon DG, 969
Singh G, *(letter)* 352
Skinner M, 760
Sloan TB, 204
Sloboda AE, (suppl 84)
Smith CA, 815
Smith CB, 647
Smith DL, *(letter)* 518
Smith H, 504
Smith LH, *(abstr)* 1,005
Smythe HA, *(editorial)* 1, *(book review)* 870, 965
Snaith ML, 599, 917
Spiegel PK, 979
Spilberg I, 689
Stangler DA, 974
Starkebaum G, 679
Stearnes GN, 321
Steele V, *(abstr)* 1,011
Sternlieb I, (suppl 94, 149)
Stevens MB, 797
Strosberg JM, *(letter)* 523
Sullivan B, 931
Sullivan SN, *(letter)* 182
Susta A, *(letter)* 864
Sutor DJ, *(abstr)* 1,004
Svejgaard A, *(editorial)* 541
Sweet JM, *(abstr)* 1,006

T

Tabbara KF, 670
Taborn JD, 165
Takeuchi A, 40
Takeuchi F, 563
Takizawa I, 19
Tanabe S, 895
Tenenbaum J, *(book review)* 358
Terasaki PI, 804
The Toronto Sun, *(editorial)* 2
The Toronto Star, *(editorial)* 3
Thevenon A, *(letter)* 521
Thomas J-L, 512
Thomas MH, 133
Thompson JM, *(book review)* 183
Thorne C, *(book review)* 1,028
Todoroki T, 910
Traub W, *(abstr)* 1,011
Traycoff RB, 494
Trevarthen D, *(letter)* 862
Troup GM, 498
Tu WH, *(letter)* 522
Turner-Warwick M, (suppl 166)

U

Ueno Y, 456, 804, 825
Uluoglu O, *(abstr)* 1,009, *(abstr)* 1,010
Urowitz MB, 741
Utturkar AB, 423

V

van Beusekom HJ, 31
van de Putte LBA, 31, 639
van den Berg WB, 31
van den Brock W,M, 31
van Ginneken CAM, 639
van Loenhout JWA, 639
Vasey FB, 621, *(letter)* 869, *(letter)* 1,026
Varghese Z, *(abstr)* 1,011
Vazquez LT, 955
Vega-Ortiz JM, 509
Verbruggen G, 45
Veys EM, 45
Viana-Queiros M, 462
Vignon E, 440, 447
Vignos PJ Jr, *(letter)* 173
Vigorita V, *(abstr)* 1,009
Vincent J, 501
Viozzi FJ, 317
Volanakis JE, *(letter)* 697

W

Wallington TB, 433
Walshe JM, (suppl 3, 124, 155)
Walz DT, 829
Ward DJ, 390
Ward JR, (suppl 124)
Wassef M, 820
Weinberger A, 380
Weinblatt ME, 685
Weiner S, *(abstr)* 1,011
Weinstein A, 331, 405
Weisman I, *(abstr)* 1,018
Weiss T, 79
Werness PG, *(abstr)* 1,005
White AG, 233
White RG, 423
Wiesner RH, (suppl 51)
Wilke WS, 626
Wilkinson S, 983
Williamson J, (suppl 169)
Wilson DA, *(letter)* 355
Wollheim FA, (suppl 74, 124), 856
Woodbury JFL, 937
Wybran J, 643

Y

Yano E, 563
Yood RA, 760
Yoshino S, 328
Youinou P, *(letter)* 174, *(letter)* 868
Young RA, *(abstr)* 1,017
Yucel A, *(abstr)* 1,009, *(abstr)* 1,010

Z

Zanetti M, 405
Ziff M, (suppl 124)
Zilko PJ, (suppl 56, 169)
Zuckner J, 79, 141, 811
Zurier RB, *(book review)* 358
Zvarova J, *(letter)* 864

The Journal of Rheumatology Volume 8

SUBJECT INDEX Pages 1-1029 and Supplement 7, 1981

A

Abstracts
symposium on crystallography in the health sciences: crystalline deposits in human tissues, 1,000
Achilles tendon
tendon rupture in SLE, 308
Acne
the musculoskeletal manifestations of acne fulminans, 317
Acne conglobata
acne rheumatism. Report of a case, 336
Acne with arthritis
the musculoskeletal manifestations of acne fulminans, 317
Acute anterior uveitis
association of HLA-A2 with uveitis in HLA-B27 positive patients with AS, 295
Acute phase protein
C-reactive protein in sera from patients with SLE, 599
Acute osteoarthropathy
acute progressive osteoarthropathy of large joints: report of three cases, 482
Adaptations of joint surface
histologic changes in rheumatoid disease of the metacarpal and metatarsal heads as seen in surgical material, 246
ADCC assay
lack of antibody in rheumatoid sera to autologous synovial macrophages and dendritic cells by antibody-dependent cellular cytotoxicity assays (ADCC), 647
Adjuvant arthritis
D-penicillamine, lymphocytes, and macrophages: an account of experimental investigation *in vivo*, suppl 62
Adult Still's disease
amyloidosis in adult onset Still's disease, 833
Adverse reactions
penicillamine in rheumatic diseases: a prospective study of tolerance and efficacy, suppl 107
$_1$-Antitrypsin-IgA complexes
effects of D-penicillamine on circulating protein complexes in RA and primary biliary cirrhosis, suppl 74
Allogeneic thymocyte
chronic polyarthritis in inbred C3H/He mice after systemic administration of allogeneic thymocytes, 895
Alpha-1-antitrypsin
antitrypsin activity and enzyme inhibitors in the rheumatoid joint, 547
Alpha-2-macroglobulin
antitrypsin activity and enzyme inhibitors in the rheumatoid joint, 547
American Indians
heterogeneity of HLA-DR4 in the RA of a Chippewa band, 797
Amyloid bone lesions
multiple myeloma and amyloid bone lesions complicating RA, 845
Amyloidosis
amyloidosis in adult onset Still's disease, 833
soft tissue uptake of bone seeking radionuclide in amyloidosis, 760
ANA
multiple ANA in MCTD: report of a patient with an unusual antibody profile, 635
Ankylosing hyperostosis
peripheral hyperostosis in RA in the absence of axial involvement, 653
Ankylosing spondylitis (AS)
association of HLA-A2 with uveitis in HLA-B27 positive patients with AS, 295
coexistence of HLA-B27 AS and DR4 seropositive nodular RA in a patient with membranous nephropathy, 661
survival among patients with AS: a life-table analysis, 86
the coexistence of RA with Reiter's syndrome and/or AS: a model of dual HLA-associated disease susceptibility and expression, 398
Annual cycles
annual fluctuations in RA, 725
Antiarthritic agents
effects of oxygen-derived free radicals on connective tissue macromolecules: inhibition by copper-penicillamine complex, suppl 9
Antibody
relapsing polychondritis associated with ulcerative colitis, serial determinations of antibodies to cartilage and circulating immune complexes by three assays, 456
Anti-collagen type II antibodies
relapsing polychondritis — pathogenic role of anti-native collagen type II antibodies: a case report with immunological and pathological studies, 820

Anti-endothelial cell antibodies
sera from patients with SLE reactive with human endothelial cells, 581
Antigen-induced synovitis
rabbit synovial tissue in culture: influence of the inflammatory state *in vivo* on the secretion of collagenase, 367
Antigens
differences of antigen composition of RA and non-RA derived tissue cultured synovial cells as detected by monkey anti-RA synovial cell sera, 204
Antiinflammatory drugs
lower gastrointestinal side effects of nonsteroidal antiinflammatory drugs, 952
Antinuclear antibodiese *(see ANA)*
MCTD – a subset with sequential clinical and laboratory features, 587
multiple ANA in MCTD: report of a patient with an unusual antibody profile, 635
Antistriational antibody
immunobiology of D-penicillamine, suppl 56
Anti-suppressor cell
suppressor T cell dysfunction and anti-suppressor cell antibody in active early RA, 9
Aplastic anemia
the side effects of penicillamine therapy in RA, suppl 146
Arthritis
costs of managing patients at a Canadian rheumatic disease unit, 937
factitial Weber-Christian disease: a case report, 129
local hyperthermia and cartilage breakdown: histochemical and metabolic studies on rabbit articular cartilage *in vitro*, 193
Reiter's syndrome following epidemic shigellosis, 969
sarcoidosis presenting as cutaneous ulceration, subcutaneous nodules and chronic arthritis, 311
synovial fluid total hemolytic complement activity in rheumatic diseases – a reappraisal, 390
Arthritis research
In memoriam, *(editorial)* 1
Arthroscopy
arthroscopic findings in the frozen shoulder, 149
Articular cartilage
cartilage matrix in hereditary pyrophosphate arthropathy, 959
local hyperthermia and cartilage breakdown: histochemical and metabolic studies on rabbit articular cartilage *in vitro*, 193
AS *(see ankylosing spondylitis)*
Assays
an overview of assay methods for D-penicillamine, suppl 28
Atlantoaxial subluxation
longterm follow-up of posterior cervical fusion for atlantoaxial subluxation in RA, 423
Atopy
incidence of atopy in rheumatic disease, 321
Auranofin
effect of auranofin dose regimen change upon cell-associated gold in RA patients, 829
Autoantibodies
autoantibody formation in D-penicillamine-treated RA, suppl 80
effects of D-penicillamine on circulating protein complexes in RA and primary biliary cirrhosis, suppl 74
the Jo-1 antibody system in myositis: relationships to clinical features and HLA, 925
Autoimmune
immunobiology of D-penicillamine, suppl 56
myasthenia gravis and D-penicillamine, suppl 169
Autoimmunity
chronic interstitial cystitis as an initial major manifestation of SLE, 808
relapsing polychondritis – pathogenic role of anti-native collagen type II antibodies: a case report with immunological and pathological studies, 820
T lymphocyte colony formation and autoimmune disease: *in vitro* assessment of immunopathology, 214
Autologous MLR
immunosuppressive effects of deflazacort – a new glucocorticoid with bone-sparing and carbohydrate-sparing properties: comparison with prednisone, 783
Avulsion quadriceps tendons
avulsion of the quadriceps tendons in a patient with an unusual deforming arthritis and varied skin lesions, 983
Azathioprine
plasma exchange in rheumatoid vasculitis, 433

B

Basic research
research is for now, too, *(editorial)* 361
Behcet's disease
association of Behcet's syndrome with HLA-B5 in the Mexican mestizo population, 325
the mechanism of hyperchemotaxis in Behcet's disease, 40
Bladder involvement
chronic interstitial cystitis as an initial major manifestation of SLE, 808

Blood gold levels
effect of auranofin dose regimen change upon cell-associated gold in RA patients, 829
Bone
soft tissue uptake of bone seeking radionuclide in amyloidosis, 760
Bone necroses
osteomalacia, pseudosacroiliitis and necrosis of the femoral heads in Fanconi syndrome in an adult, 512
Bowed fingers
bowed fingers. A helpful sign in the early diagnosis of systemic sclerosis, 266
Bronchiolitis
adverse reactions affecting the lung: possible association with D-penicillamine, suppl 166
Brucella arthritis
reactive arthritis associated with brucellosis: HLA studies, 621

C

C4 deficiency
SLE in a patient with C4 deficiency, 741
C-reactive protein
annual fluctuations in RA, 725
C-reactive protein in sera from patients with SLE, 599
C-reactive protein in the differential diagnosis between infection and disease reactivation in SLE, 291
Cadmium
penicillamine in metal poisoning, suppl 96
Calcium
soft tissue uptake of bone seeking radionuclide in amyloidosis, 760
Calcium pyrophosphate
calcium pyrophosphate crystal formation in model hydrogels. II. hyaline articular cartilage as a gel, 451
Calcium pyrophosphate deposition disease
calcium pyrophosphate dihydrate deposition disease and familial hypomagnesemia, 767
Calcium pyrophosphate dihydrate
calcium pyrophosphate dihydrate deposition disease and familial hypomagnesemia, 767
the effect of calcium and magnesium ions on calcium pyrophosphate crystal formation in aqueous solutions, 772
Calcium pyrophosphate dihydrate deposition
calcium pyrophosphate dihydrate deposition in lumbar disc fibrocartilage, 955
Calcium pyrophosphate dihydrate deposition disease
successful use of colchicine in acute polyarticular pseudogout, 689
Calcium pyrophosphate solution chemistry
the effect of calcium and magnesium ions on calcium pyrophosphate crystal formation in aqueous solutions, 772
Canine
copper toxicosis of the Bedlington terrier, suppl 94
Carpal tunnel syndrome
eosinophilic fasciitis complicated by carpal tunnel syndrome, 856
Cartilage
macroscopically normal cartilage from the human OA femoral head. I. histological evaluation, 440
macroscopically normal cartilage from the human OA femoral head. II. measurement of cartilage thickness and cell density, 447
relapsing polychondritis associated with ulcerative colitis, serial determinations of antibodies to cartilage and circulating immune complexes by three assays, 456
Cartilage cell density
macroscopically normal cartilage from the human OA femoral head. II. measurement of cartilage thickness and cell density, 447
Cartilage crystals
calcium pyrophosphate crystal formation in model hydrogels. II. hyaline articular cartilage as a gel, 451
Cartilage histology
macroscopically normal cartilage from the human OA femoral head. I. histological evaluation, 440
Cartilage thickness
macroscopically normal cartilage from the human OA femoral head. II. measurement of cartilage thickness and cell density, 447
Causes of eosinophilic fasciitis
eosinophilic fasciitis — new associations and current perspectives, *(editorial)* 6
Cell-associated gold
effect of auranofin dose regimen change upon cell-associated gold in RA patients, 829
Cell culture
uridine diphosphate glucose dehydrogenase in rheumatoid synovial cells in culture, 710
Cell fractionation
the mechanism of hyperchemotaxis in Behcet's disease, 40
Cell-mediated immunity
cell-mediated immune response of synovial mononuclear cells to sexually transmitted, enteric and mumps antigens in patients with Reiter's syndrome, RA and AS, 220

Cellular immunity
decreased numbers of monocytes in inflammatory exudates in SLE, 62
Ceruloplasmin
Wilson's disease, suppl 90
Cervical fusion
longterm follow-up of posterior cervical fusion for atlantoaxial subluxation in RA, 423
Charcot joints
neuroarthropathy (Charcot joints) in familial amyloid polyneuropathy, 477
Chelating agent
the discovery of the therapeutic use of D-penicillamine, suppl 3
Chelation
copper penicillaminate for RA, suppl 178
penicillamine in metal poisoning, suppl 96
Wilson's disease, suppl 90
Chemotactic factor
demonstration of chemotactic factor in human gout: further characterization of occurrence and structure, 889
Chemotaxis
demonstration of chemotactic factor in human gout: further characterization of occurrence and structure, 889
the mechanism of hyperchemotaxis in Behcet's disease, 40
Chlorambucil
chlorambucil in the treatment of iridocyclitis in JRA, 141
Cholestasis
the syndrome of primary biliary cirrhosis, suppl 121
Cholesterol crystals
cholesterol crystals in osteoarthritic joint effusions, 273
experimental cholesterol crystal arthropathy, 281
rheumatoid subcutaneous bursitis, 974
Chondrocalcinosis
acute pseudogout and chondrocalcinosis in a man with mild hemophilia, 841
calcium pyrophosphate dihydrate deposition disease and familial hypomagnesemia, 767
cartilage matrix in hereditary pyrophosphate arthropathy, 959
Chromatography
a survey of analytical approaches to the measurement of D-penicillamine and penicillamine disulfides, suppl 20
Chronic
sacroidosis presenting as cutaneous ulceration, subcutaneous nodules and chronic arthritis, 311
Chronic active hepatitis
subclinical liver disease in SLE, 752
Chronic arthritis of childhood
penicillamine in chronic arthritis of childhood, suppl 112
Chronic hereditary lymphedema
transudative knee effusions in Milroy's disease, 670
Chronic interstitial cystitis
chronic interstitial cystitis as an initial major manifestation of SLE, 808
Chronic neutropenia
chronic neutropenia: possible association with Sjögren's syndrome, 679
Circulating immune complexes
reactive arthritis associated with brucellosis: HLA studies, 621
Classification of gonococcal arthritis
patterns of gonococcal arthritis, *(editorial)* 707
Climate
annual fluctuations in RA, 725
Clinical research
research is for now, too, *(editorial)* 361
Coexistence
coexistence of chronic tophaceous gout and RA, 989
Colchicine
successful use of colchicine in acute polyarticular pseudogout, 689
Clofazimin
acne rheumatism. Report of a case, 336
Collagen
PSS and penicillamine, suppl 116
Collagen gelation
effects of oxygen-derived free radicals on connective tissue macromolecules: inhibition by copper-penicillamine complex, suppl 9
Collagenase
lack of antibody in rheumatoid sera to autologous synovial macrophages and dendritic cells by antibody-dependent cellular cytotoxicity assays (ADCC), 647
rabbit synovial tissue in culture: influence of the inflammatory state *in vivo* on the secretion of collagenase, 367
Community rheumatology
community rheumatology practice in Thunder Bay. A Canadian experience from Northwestern Ontario, 119
Complement
immune complexes in polyarthritis after salmonella gastroenteritis, 613
inhibition of complement by gold sodium thiomalate, 57
synovial fluid total hemolytic complement activity in rheumatic diseases — a reappraisal, 390

suppression of Fc receptor and C4.C3 receptors of the granulocytes from patients with SLE, 910
Compliance
noncompliance with arthritis drugs: magnitude, correlates, and clinical implications, 931
Computed tomography
early diagnosis of septic arthritis of the sacroiliac joint by use of computed tomography, 979
Concanavalin A
D-penicillamine, lymphocytes, and macrophages: an account of experimental investigation *in vivo*, suppl 62
Connective tissue diseases
oxy radicals and connective tissue, *(editorial)* 185
Control studies
plasma exchange in RA, *(editorial)* 364
Copper
effects of oxygen-derived free radicals on connective tissue macromolecules: inhibition by copper-penicillamine complex, suppl 9
the discovery of the therapeutic use of D-penicillamine, suppl 3
the syndrome of primary biliary cirrhosis, suppl 121
Copper in arthritis
free-radical oxidation (peroxidation) products in serum and synovial fluid in RA, 233
Copper metabolism
Wilson's disease, suppl 90
Copper penicillaminate
copper penicillaminate for RA, suppl 178
Copper toxicity
copper toxicosis of the Bedlington terrier, suppl 94
Corticosteroids
tendon rupture in SLE, 308
Cost analysis
costs of managing patients at a Canadian rheumatic disease unit, 937
Cost benefit
costing: in search of a question, *(editorial)* 873
costs of managing patients at a Canadian rheumatic disease unit, 937
Cost effectiveness
costing: in search of a question, *(editorial)* 873
costs of managing patients at a Canadian rheumatic disease unit, 937
Crystal arthropathy
the effect of calcium and magnesium ions on calcium pyrophosphate crystal formation in aqueous solutions, 772
Crystal-induced arthritis
successful use of colchicine in acute polyarticular pseudogout, 689
Crystalline arthritis
experimental cholesterol crystal arthropathy, 281
Crystalline deposits
symposum on crystallography in the health sciences: crystalline deposits in human tissues, *(introduction)* 997
Crystals
demonstration of chemotactic factor in human gout: further characterization of occurrence and structure, 889
Cultured human arterial smooth muscle cells
in vitro lymphocyte cytotoxicity to cultured human arterial smooth muscle cells in patients with giant cell arteritis and polymyalgia rheumatica, 125
Cutaneous
sarcoidosis presenting as cutaneous ulceration, subcutaneous nodules and chronic arthritis, 311
Cyclopophamide
plasma exchange in rheumatoid vasculitis, 433
Cystine excretion
experience with penicillamine in the treatment of cystinuria, suppl 100
Cystinuria
experience with penicillamine in the treatment of cystinuria, suppl 100
the metabolism and pharmacology of D-penicillamine in man, suppl 41
Cystitis
chronic interstitial cystitis as an initial major manifestation of SLE, 808

D

D-penicillamine
an overview of assay methods for D-penicillamine, suppl 28
D-penicillamine, lymphocytes, and macrophages: an account of experimental investigation *in vivo*, suppl 62
effects of D-penicillamine on circulating protein complexes in RA and primary biliary cirrhosis, suppl 74
levamisole in RA: a comparison with D-penicillamine, 575
modulation of human antibody production *in vitro* by D-penicillamine and $CuCO_4$: inhibition of helper T cell function, suppl 69
plasma exchange therapy for severe penicillamine-induced myasthenia gravis, 303
proteinuria in D-penicillamine-treated RA, suppl 161
studies on the effect of D-penicillamine on type II collagen-induced polyarthritis, suppl 84
the pharmacokinetics of D-penicillamine in man, suppl 51

D-penicillamine metabolism
the metabolism and pharmacology of D-penicillamine in man, suppl 41
Deflazacort
immunosuppressive effects of deflazacort — a new glucocorticoid with bone-sparing and carbohydrate-sparing properties: comparison with prednisone, 783
Deforming arthritis
avulsion of the quadriceps tendons in a patient with an unusual deforming arthritis and varied skin lesions, 983
Degeneration
local hyperthermia and cartilage breakdown: histochemical and metabolic studies on rabbit articular cartilage *in vitro*, 193
Degenerative joint disease
Heberden's nodes' nails, 509
Dermatomyositis
MCTD — a decade of growing pains, *(editorial)* 535
the Jo-1 antibody system in myositis: relationships to clinical features and HLA, 925
Dermatopathy
penicillamine-induced skin lesions, suppl 149
Detection of immune complexes
the significance and limitations of current methods for detecting circulating immune complexes, *(editorial)* 188
Differential diagnosis
synovial fluid total hemolytic complement activity in rheumatic diseases — a reappraisal, 390
Diffuse connective tissue disease
MCTD — a decade of growing pains, *(editorial)* 535
Diffuse idiopathic skeletal hyperostosis *(see also DISH)*
peripheral hyperostosis in RA in the absence of axial involvement, 653
Diflunisal hypouricemic effect
persistent hypouricemic effect of longterm diflunisal administration, 639
Direct muscle immunofluorescence
muscle disease in SLE: a study of its nature, frequency and cause, 917
Disease activity
circulating immune complexes in patients with RA: correlation with disease activity, 851
Dish
marked hyperinsulinemia after glucose challenge in patients with diffuse idiopathic skeletal hyperostosis, 965
Disulfides
a survey of analytical approaches to the measurement of D-penicillamine and penicillamine disulfides, suppl 20
DNA-antiDNA complexes
phagocytosis and degradation of DNA-antiDNA complexes by human phagocytes. Influence of rheumatoid factors, 880
Drug treatment
synovial fluid total hemolytic complement activity in rheumatic diseases — a reappraisal, 390
Drugs
noncompliance with arthritis drugs: magnitude, correlates, and clinical implications, 931

E

Early active RA
suppressor T cell dysfunction and anti-suppressor cell antibody in active early RA, 9
Education
a controlled study of group counseling in RA, 91
Edward A. Dunlop
In memoriam, *(editorial)* 1
Ehlers-Danlos
Ehlers-Danlos syndrome presenting as rheumatic manifestations in the child, 79
Elastosis perforans
penicillamine-induced skin lesions, suppl 149
Electron microscopy
experimental joint trauma: synovial response to blunt trauma and inflammatory reaction to intraarticular injection of fat, 380
non-Hodgkin's lymphoma in SLE. Report of 4 cases with ultrastructural studies in 2, 69
ENA antibodies
MCTD — a decade of growing pains, *(editorial)* 535
Endothelial cells
sera from patients with SLE reactive with human endothelial cells, 581
Eosinophilic fasciitis
eosinophilic fasciitis complicated by carpal tunnel syndrome, 856
new associations and current perspectives, *(editorial)* 6
Epiphyses of fingers
Thiemann's disease, 462
Epstein-Barr virus
coexistence of RA in married couples: a search for etiological factors, 416
E rosettes
in vitro responses of lymphocytes in juvenile arthritis: effects of time and concentration of PHA-P, 716
Erythrocyte inclusions
concurrent SLE and salmonellosis, 605
Erythrocyte sedimentation rate
annual fluctuations in RA, 725

EULAR
the International League Against Rheumatism, *(editorial)* 705
Eperimental arthritis
^{99m}Tc-pertechnetate uptake measurement in the rabbit knee-joint. I. Standardization of the method and measurements in experimental arthritis, 31
Experimental polyarthritis
chronic polyarthritis in inbred C3H/He mice after systemic administration of allogeneic thymocytes, 895
Extractable nuclear antigen
MCTD – a subset with sequential clinical and laboratory features, 587

F

Factitial Weber-Christian disease
factitial Weber-Christian disease: a case report, 129
Familial amyloidosis
neuroarthropathy (Charcot joints) in familial amyloid polyneuropathy, 477
Fanconi syndrome in an adult
osteomalacia, pseudosacroiliitis and necrosis of the femoral heads in Fanconi syndrome in an adult, 512
Felty's syndrome
Felty's syndrome: case report and rationale for disease-suppressant immunosuppressive therapy, 791
Felty's syndrome: response to parenteral gold, 902
gold in the treatment of Felty's syndrome, *(editorial)* 878
Fiax fluorometer
a quantitative immunofluorescence assay for IgM rheumatoid factor, 837
Fibrosis
PSS and penicillamine, suppl 116
Fibrositis
hypothyroidism with presenting symptoms of fibrositis, 626
Forestier's disease
peripheral hyperostosis in RA in the absence of axial involvement, 653
Foreword
Proceedings International Symposium on Penicillamine, Miami, Florida, U.S.A., May 8-9, 1980, suppl 1
Free radicals
free-radical oxidation (peroxidation) products in serum and synovial fluid in RA, 233
Frozen shoulder
arthroscopic findings in the frozen shoulder, 149

G

Gastrointestinal side effects
lower gastrointestinal side effects of nonsteroidal antiinflammatory drugs, 952
Genetic factors
genetic factors in SLE, 347
Genetic markers
association of Behcet's syndrome with HLA-B5 in the Mexican mestizo population, 325
Giant cell arteritis
HLA-DR locus antigens in polymyalgia rheumatica and giant cell arteritis, 993
in vitro lymphocyte cytotoxicity to cultured human arterial smooth muscle cells in patients with giant cell arteritis and polymyalgia rheumatica, 125
Glucose tolerance
marked hyperinsulinemia after glucose challenge in patients with diffuse idiopathic skeletal hyperostosis, 965
Glutathione
D-penicillamine-induced increase in intracellular glutathione correlating to clinical response in RA, suppl 14
Glycosaminoglycans
cartilage matrix in hereditary pyrophosphate arthropathy, 959
Gold
Felty's syndrome: case report and rationale for disease-suppressant immunosuppressive therapy, 791
levamisole – a possible alternative to gold and penicillamine in the longterm treatment of RA, 730
penicillamine in metal poisoning, suppl 96
penicillamine in the treatment of RA, suppl 103
Gold salts
a study of the response of the leukopenia of RA to gold salt therapy, 658
gold in the treatment of Felty's syndrome, *(editorial)* 878
Gold therapy
penicillamine in rheumatic diseases: a prospective study of tolerance and efficacy, suppl 107
Gold sodium thiomalate
inhibition of complement by gold sodium thiomalate, 57
Gonococcal arthritis
patterns of gonococcal arthritis, *(editorial)* 707
Goodpasture's syndrome
adverse reactions affecting the lung: possible association with D-penicillamine, suppl 166

Gout
a gouty family with increased phosphoribosylpyrophosphate synthetase activity: case reports, familial studies, and kinetic studies of the abnormal enzyme, 563
coexistence of chronic tophaceous gout and RA, 989
demonstration of chemotactic factor in human gout: further characterization of occurrence and structure, 889
interactions of murine macrophages with monosodium urate crystals: stimulation of lysosomal enzyme release and prostaglandin synthesis, 555
Group counseling
a controlled study of group counseling in RA, 91
Growth hormone
marked hyperinsulinemia after glucose challenge in patients with diffuse idiopathic skeletal hyperostosis, 965
Growth of rheumatology
the growth of rheumatology, *(editorial)* 4

H

Heberden's nodes
Heberden's nodes' nails, 509
Helper T cells
modulation of human antibody production *in vitro* by D-penicillamine and $CuSO_4$: inhibition of helper T cell function, suppl 69
Hemolytic anemia
hypertrophic osteoarthropathy and pseudomembranous enterocolitis, 825
Hemophilia
acute pseudogout and chondrocalcinosis in a man with mild hemophilia, 841
Hemorrhagic effusion
monarticular arthritis: early manifestation of a rhabdomyosarcoma, 685
Hidden 19S IgM RF
hidden 19S IgM rheumatoid factor in synovial fluid, 811
HLA-A2
association of HLA-A2 with uveitis in HLA-B27 positive patients with AS, 295
HLA antigen
heterogeneity of HLA-DR4 in the RA of a Chippewa band, 797
immunology of D-penicillamine, suppl 56
HLA-DR locus antigens in polymyalgia rheumatica and giant cell arteritis, 993
HLA in rheumatology, *(editorial)* 541
the coexistence of RA with Reiter's syndrome and/or AS: a model of dual HLA-associated disease susceptibility and expression, 398
reactive arthritis associated with brucellosis: HLA studies, 621
the Jo-1 antibody system in myositis: relationships to clinical features and HLA, 925
HLA-B5
association of Behcet's syndrome with HLA-B5 in the Mexican mestizo population, 325
HLA-B27
association of HLA-A2 with uveitis in HLA-B27 positive patients with AS, 295
HLA in rheumatology, *(editorial)* 541
Reiter's syndrome following epidemic shigellosis, 969
the association of retroperitoneal fibrosis with systemic vasculitis and HLA-B27: a case report and a review of the literature, 665
HLA-D/DR system
HLA in rheumatology, *(editorial)* 541
HLA-DR4
coexistence of HLA-B27 AS and DR4 seropositive nodular RA in a patient with membranous nephropathy, 661
coexistence of RA in married couples: a search for etiological factors, 416
HLA-DR4 in Negro and Mexican RA patients, 804
HLA in the rheumatic diseases
HLA in rheumatology, *(editorial)* 541
Hospital costs for arthritis
costing: in search of a question, *(editorial)* 873
Hospitals
costs of managing patients at a Canadian rheumatic disease unit, 937
Hyaluronic acid
effects of oxygen-derived free radicals on connective tissue macromolecules: inhibition by copper-penicillamine complex, suppl 9
Hypermobility
Ehlers-Danlos syndrome presenting as rheumatic manifestations in the child, 79
Hyperthermia
local hyperthermia and cartilage breakdown: histochemical and metabolic studies on rabbit articular cartilage *in vitro*, 193
Hypertrophic osteoarthropathy
hypertrophic osteoarthropathy and pseudomembranous enterocolitis, 825
Hyperuricemia
a gouty family with increased phosphoribosylpyrophosphate synthetase activity: case reports, familial studies, and kinetic studies of the abnormal enzyme, 563
Hypogammaglobulinemia
rice bodies in hypogammaglobulinemic arthritis, 165

Hypomagnesemia
calcium pyrophosphate dihydrate deposition disease and familial hypomagnesemia, 767
Hypothyroidism
hypothyroidism with presenting symptoms of fibrositis, 626

I

Ibuprofen
lower gastrointestinal side effects of nonsteroidal antiinflammatory drugs, 952
IgE
incidence of atopy in rheumatic disease, 321
IgE RF
IgE rheumatoid factor in a case of RA with pleuritis, 299
IgM rheumatoid factor assay
a quantitative immunofluorescence assay for IgM rheumatoid factor, 837
ILAR
the International Leage Against Rheumatism, *(editorial)* 705
Immune complexes (IC) (CIC)
chronic interstitial cystitis as an initial major manifestation of SLE, 808
circulating IC in patients with RA: correlation with disease activity, 851
correlation of disease activity in systemic necrotizing vasculitis with IC, 258
effects of D-penicillamine on circulating protein complexes in RA and primary biliary cirrhosis, suppl 74
IC in polyarthritis after salmonella gastroenteritis, 613
plasma exchange in RA, *(editorial)* 364
plasma exchange in rheumatoid vasculitis, 433
relapsing polychondritis associated with ulcerative colitis, serial determinations of antibodies to cartilage and CIC by three assays, 456
suppression of Fc receptor and C4.C3 receptors of the granulocytes from patients with SLE, 910
the significance and limitations of current methods for detecting CIC, *(editorial)* 188
Immune complexes and disease
the significance and limitations of current methods for detectng CIC, *(editorial)* 188
Immune complex nephritis
penicillamine and the SLE syndrome, suppl 155
Immunoglobulin deficiency
hypertrophic osteoarthropathy and pseudomembranous enterocolitis, 825
Immunoglobulin secretion
modulation of human antibody production *in vitro* by D-penicillamine and $CuSO_4$: inhibition of helper T cell function, suppl 69
Immunomodulation
inosiplex: a novel treatment in RA?, 643
Immunoregulation
antigen-specific suppressor cell activity in patients with sleroderma, 747
Immunoregulatory disturbance
the potential role of immunoregulatory disturbance in the pathogenesis of SLE, 340
Immunosuppressive effects of glucocorticoids
immunosuppressive effects of deflazacort – a new glucocorticoid with bone-sparing and carbohydrate-sparing properties: comparison with prednisone, 783
Indomethacin
in vitro responses of lymphocytes in juvenile arthritis: effects of time and concentrations of PHA-P, 716
Infection
C-reactive protein in the differential diagnosis between infection and disease reactivation in SLE, 291
Infection in SLE
bacterial monarthritis due to *Neisseria meningitidis* in SLE, 145
Infectious arthritis
bacterial monarthritis due to *Neisseria meningitidis* in SLE, 145
pyogenic sacroiliitis, 157
septic arthritis due to *Kingella (Moraxella) Kingii:* case report and review of the literature, 501
Inflammation
demonstration of chemotactic factor in human gout: further characterization of occurrence and structure, 889
Inosiplex
inosiplex: a novel treatment in RA?, 643
Insulin *(see also DISH)*
marked hyperinsulinemia after glucose challenge in patients with diffuse idiopathic skeletal hyperostosis, 965
Intervertebral disc space
septic discitis, 100
Introduction
Proceedings International Symposium on Penicillamine, Miami, Florida, U.S.A., May 8-9, 1980, suppl 1
symposium on crystallography in the health sciences: crystalline deposits in human tissues, 1,000
Iridocyclitis
chlorambucil in the treatment of iridocyclitis in JRA, 141

J

Joint inflammation
oxy radicals and connective tissue, *(editorial)* 185

Joints
experimental joint trauma: synovial response to blunt trauma and inflammatory reaction to intraarticular injection of fat, 380
JRA *(see juvenile rheumatoid arthritis)*
Juvenile arthritis
in vitro responses of lymphocytes in juvenile arthritis: effects of time and concentration of PHA-P, 716
Juvenile chronic arthritis
incidence of atopy in rheumatic disease, 321
Juvenile rheumatoid arthritis (JRA)
chlorambucil in the treatment of iridocyclitis in JRA, 141
hidden 19S IgM rheumatoid factor in synovial fluid, 811
penicillamine in chronic arthritis of childhood, suppl 112

K

Kinetics of cell response
in vitro responses of lymphocytes in juvenile arthritis: effects of time and concentration of PHA-P, 716
Kingella
septic arthritis due to *Kingella (Moraxella) Kingii:* case report and review of the literature, 501
Knee effusion
transudative knee effusions in Milroy's disease, 670

L

Large joints
acute progressive osteoarthropathy of large joints: report of three cases, 482
Lead
penicillamine in metal poisoning, suppl 96
Leukopenia
a study of the response of the leukopenia of RA to gold salt therapy, 658
Felty's syndrome: response to parenteral gold, 902
gold in the treatment of Felty's syndrome, *(editorial)* 878
hematologic toxicity from penicillamine in RA, suppl 164
Levamisole
a double-blind comparison of high and low doses of levamisole in RA, 949
levamisole – a possible alternative to gold and penicillamine in the longterm treatment of RA?, 730
levamisole as basic treatment of RA: longterm evaluation, 45
levamisole in RA: a comparison with D-penicillamine, 575
Life-table analysis
survival among patients with AS: a life-table analysis, 86
Lipid
experimental joint trauma: synovial response to blunt trauma and inflammatory reaction to intraarticular injection of fat, 380
Liver
copper toxicosis of the Bedlington terrier, suppl 94
Liver disease
diagnosis of rheumatic fever obscured by liver disease, 138
Liver enzymes
subclinical liver disease in SLE, 752
Long-acting drugs
pyrithioxine and thiopronine: new penicillamine-like drugs in RA, suppl 175
Longterm evaluation
levamisole as basic treatment of RA: longterm evaluation, 45
Lumbar disc fibrocartilage
calcium pyrophosphate dihydrate deposition in lumbar disc fibrocartilage, 955
Lupus
penicillamine-induced skin lesions, suppl 149
Lupus nephritis
the coexistence of RA and SLE: a case report and review of the literature, 405
Lymphocyte cytotoxicity
in vitro lymphocyte cytotoxicity to cultured human arterial smooth muscle cells in patients with giant cell arteritis and polymyalgia rheumatica, 125
Lymphocyte transformation
T lymphocyte colony formation and antoimmune disease: *in vitro* assessment of immunopathology, 214
Lymphocytes
D-penicillamine, lymphocytes, and macrophages: an account of experimental investigation *in vivo*, suppl 62
Lymphoma
non-Hodgkin's lymphoma in SLE. Report of 4 cases with ultrastructural studies in 2, 69
Lysosomal enzymes
antitrypsin activity and enzyme inhibitors in the rheumatoid joint, 547
interactions of murine macrophages with monosodium urate crystals: stimulation of lysosomal enzyme release and prostaglandin synthesis, 555

M

Macrophages
- D-penicillamine, lymphocytes, and macrophages: an account of experimental investigation *in vivo*, suppl 62
- interactions of murine macrophages with monosodium urate crystals: stimulation of lysosomal enzyme release and prostaglandin synthesis, 555

Magnesium ions
- the effect of calcium and magnesium ions on calcium pyrophosphate crystal formation in aqueous solutions, 772

MCTD
- MCTD – a decade of growing pains, *(editorial)* 535
- MCTD – a subset with sequential clinical and laboratory features, 587
- multiple antinuclear antibodies in MCTD: report of a patient with an unusual antibody profile, 635
- Raynaud's phenomenon and initially seronegative MCTD, 632

Medication
- noncompliance with arthritis drugs: magnitude, correlates, and clinical implications, 931

Membranous nephropathy
- coexistence of HLA-B27 AS and DR4 seropositive nodular RA in a patient with membranous nephropathy, 661

Meningococcal arthritis
- bacterial monarthritis due to *Neisseria meningitidis* in SLE, 145

Metabolism
- local hyperthermia and cartilage breakdown: histochemical and metabolic studies on rabbit articular cartilage *in vitro*, 193
- metabolism and pharmacokinetics of penicillamine in rats – an overview, suppl 35

Metacarpals
- histologic changes in rheumatoid disease of the metacarpal and metatarsal heads as seen in surgical material, 246

Metal poisoning
- penicillamine in metal poisoning, suppl 96

Metatarsals
- histologic changes in rheumatoid disease of the metcarpal and metatarsal heads as seen in surgical material, 246

Microbial agents
- the potential role of microbial agents in the pathogenesis of SLE, 344

Milroy's disease
- transudative knee effusions in Milroy's disease, 670

Mixed connective tissue disease *(see MCTD)*

Monarthritis
- monarticular arthritis: early manifestations of a rhabdomyosarcoma, 685

Monocyte function
- decreased numbers of monocytes in inflammatory exudates in SLE, 62

Monocytes
- phagocytosis and degradation of DNA-antiDNA complexes by human phagocytes. Influence of rheumatoid factors, 880

Monosodium urate
- interactions of murine macrophages with monosodium urate crystals: stimulation of lysosomal enzyme release and prostaglandin synthesis, 555

Monosodium urate monohydrate
- inhibition of complement by gold sodium thiomalate, 57

Moraxella
- septic arthritis due to *Kingella (Moraxella) Kingii:* case report and review of the literature, 501

Motivation
- results of surgical treatment of nonambulatory rheumatoid patients, 328

Muscle symptoms
- muscle disease in SLE: a study of its nature, frequency and cause, 917

Myasthenia gravis
- immunobiology of D-penicillamine, suppl 56
- myasthenia gravis and D-penicillamine, suppl 169
- plasma exchange therapy for severe penicillamine-induced myasthenia gravis, 303

Myeloma
- multiple myeloma and amyloid bone lesions complicating RA, 845

Myositis
- localized nodular myositis, 815

Myxoma
- myxoma masquerading as polyarteritis nodosa, 133

N

Nail changes
- Heberden's nodes' nails, 509

Naproxen
- lower gastrointestinal side effects of nonsteroidal antiinflammatory drugs, 952

Natural course
- eosinophilic fasciitis complicated by carpal tunnel syndrome, 856

Necrotizing vasculitis
- avulsion of the quadriceps tendons in a patient with an unusual deforming arthritis and varied skin lesions, 983

Nephritis
- proteinuria in D-penicillamine-treated RA, suppl 161

Nephrotic syndrome
proteinuria in D-penicillamine-treated RA, suppl 161
Neuroarthropathy
neuroarthropathy (Charcot joints) in familial amyloid polyneuropathy, 477
Neuropathic joints
neuroathropathy (Charcot joints) in familial amyloid polyneuropathy, 477
Neutrophil
the mechanism of hyperchemotaxis in Behcet's disease, 40
Neutrophils
phagocytosis and degradation of DNA-antiDNA complexes by human phagocytes. Influence of rheumatoid factors, 880
^{99m}Technetium pertechnetate
^{99m}Tc-pertechnetate uptake measurement in the rabbit knee joint — I. Standardization of the method and measurements in experimental arthritis, 31
Nodules
sarcoidosis presenting as cutaneous ulceration, subcutaneous nodules and chronic arthritis, 311
Nonambulatory rheumatoid patient
results of surgical treatment of nonambulatory rheumatoid patients, 328
Non inflammatory
acute progressive osteoarthropathy of large joints: report of three cases, 482

O

OA *(see osteoarthritis)*
Oral chrysotherapy
effect of auranofin dose regimen change upon cell-associated gold in RA patients, 829
Organization
regional rheumatology practice in Umea — a Northern Swedish experience, 110
Osteoarthritis (OA)
cholesterol crystals in OA joint effusions, 273
macroscopically normal cartilage from the human OA femoral head. I. histological evaluation, 440
macroscopically normal cartilage from the human OA femoral head. II. measurement of cartilage thickness and cell density, 447
stress fractures associated with adjacent OA, 161
Osteoarthrosis
Heberden's nodes' nails, 509
Osteomalacia
osteomalacia, pseudosacroiliitis and necrosis of the femoral heads in Fanconi syndrome in an adult, 512
Oxy radicals
oxy radicals and connective tisue, *(editorial)* 185

P

PANLAR
the International League Against Rheumatism, *(editorial)* 705
Panniculitis
factitial Weber-Christian disease: a case report, 129
Parenteral gold therapy
Felty's syndrome: response to parenteral gold, 902
Pathogenesis of eosinophilic fasciitis
eosinophilic fasciitis — new associations and current perspectives, *(editorial)* 6
Pathogenesis of SLE
the potential role of immunoregulatory disturbance in the pathogenesis of SLE, 340
the potential role of microbial agents in the pathogenesis of SLE, 344
Pemphigus
penicillamine-induced skin lesions, suppl 149
Penicillamine
a survey of analytical approaches to the measurement of D-penicillamine and penicillamine disulfides, suppl 20
adverse reactions affecting the lung: possible association with D-penicillamine, suppl 166
autoantibody formation in D-penicillamine-treated RA, suppl 80
copper penicillaminate for RA, suppl 178
copper toxicosis of the Bedlington terrier, suppl 94
effects of oxygen-derived free radicals on connective tissue macromolecules: inhibition by copper-penicillamine complex, suppl 9
foreword, Proceedings International Symposium on Penicillamine, Miami, Florida, U.S.A., May 8-9, 1980, suppl 1
hematologic toxicity from penicillamine in RA, suppl 164
immunobiology of D-penicillamine, suppl 56
introduction, Proceedings International Symposium on Penicillamine, Miami, Florida, U.S.A. May 8-9, 1980, suppl 1
levamisole — a possible alternative to gold and penicillamine in the longterm treatment of RA?, 730
metabolism and pharmacokinetics of penicillamine in rats — an overview, suppl 35
myasthenia gravis and D-penicillamine, suppl 169
other penicillamine-like drugs, suppl 180
penicillamine and the SLE syndrome, suppl 155
penicillamine in chronic arthritis of childhood, suppl 112
penicillamine in metal poisoning, suppl 96
penicillamine in the treatment of RA, suppl 103
penicillamine-induced skin lesions, suppl 149

PSS and penicillamine, suppl 116
the discovery of the therapeutic use of D-penicillamine, suppl 3
the side effects of penicillamine therapy in RA, suppl 146
the syndrome of primary biliary cirrhosis, suppl 121
Wilson's disease, suppl 90
Penicillamine disulfide
copper penicillaminate for RA, suppl 178
Penicillamine dosage
experience with penicillamine in the treatment of cystinuria, suppl 100
Penicillamine therapy
D-penicillamine-induced increase in intracellular glutathione correlating to clinical response in RA, suppl 14
penicillamine in rheumatic diseases: a prospective study of tolerance and efficacy, suppl 107
PHA-P response
in vitro responses of lymphocytes in juvenile arthritis: effects of time and concentration of PHA-P, 716
Phagocytosis
phagocytosis and degradation of DNA-antiDNA complexes by human phagocytes. Influence of rheumatoid factors, 880
Pharmacokinetics
metabolism and pharmacokinetics of penicillamine in rats – an overview, suppl 35
Phosphoribosylpyrophosphate synthetase
a gouty family with increased phosphoribosylpyrophosphate synthetase activity: case reports, familial studies, and kinetic studies of the abnormal enzyme, 563
Phytohemagglutinin stimulation
in vitro lymphocyte response in early RA, 468
PIP joints
Thiemann's disease, 462
Plasma exchange
plasma exchange in RA, *(editorial)* 364
plasma exchange in rheumatoid vasculitis, 433
plasma exchange therapy for severe penicillamine-induced myasthenia gravis, 303
Plasma proteins
eosinophilic fasciitis complicated by carpal tunnel syndrome, 856
Plasmapheresis
plasma exchange in RA, *(editorial)* 364
Pleuritis
IgE rheumatoid factor in a case of RA with pleuritis, 299
Pokeweed mitogen
suppressor T cell dysfunction and depressed immunoglobulin production by B cells *in vitro* in patients with SLE, 19
Polyarteritis
myxoma masquerading as polyarteritis nodosa, 133
Polyarthralgia
Ehlers-Danlos syndrome presenting as rheumatic manifestations in the child, 79
Polyarthritis
acne rheumatism. Report of a case, 336
Polychondritis
relapsing polychondritis associated with ulcerative colitis, serial determinations of antibodies to cartilage and circulating immune complexes by three assays, 456
Polymyositis
localized nodular myositis, 815
the Jo-1 antibody system in myositis: relationships to clinical features and HLA, 925
Polymyalgia rheumatica
HLA-DR locus antigens in polymyalgia rheumatica and giant cell arteritis, 993
in vitro lymphocyte cytotoxicity to cultured human arterial smooth muscle cells in patients with giant cell arteritis and polymyalgia rheumatica, 125
Polymyositis
MCTD – a decade of growing pains, *(editorial)* 535
Polyneuropathy
neuroarthropathy (Charcot joints) in familial amyloid polyneuropathy, 477
Prednisone
Felty's syndrome: case report and rationale for disease-suppressant immunosuppressive therapy, 791
Primary biliary cirrhosis
effects of D-penicillamine on circulating protein complexes in RA and primary biliary cirrhosis, suppl 74
the syndrome of primary biliary cirrhosis, suppl 121
Progressive
acute progressive osteoarthropathy of large joints: report of three cases, 482
Progressive systemic sclerosis (PSS)
antigen-specific suppressor cell activity in patients with scleroderma, 747
PSS and penicillamine, suppl 116
Prostaglandins
interactions of murine macrophages with monosodium urate crystals: stimulation of lysosomal enzyme release and prostaglandin synthesis, 555
Protein binding
experience with penicillamine in the treatment of cystinuria, suppl 100

Proteinuria
experience with penicillamine in the treatment of cystinuria, suppl 100
hypertrophic osteoarthropathy and pseudomembranous enterocolitis, 825
proteinuria in D-penicillamine-treated RA, suppl 161
the side effects of penicillamine therapy in RA, suppl 146
Proteoglycans
cartilage matrix in hereditary pyrophosphate arthropathy, 959
Pseudogout
acute pseudogout and chondrocalcinosis in a man with mild hemophilia, 841
calcium pyrophosphate dihydrate deposition disease and familial hypomagnesemia, 767
successful use of colchicine in acute polyarticular pseudogout, 689
Pseudomembranous enterocolitis
hypertrophic osteoarthropathy and pseudomembranous enterocolitis, 825
Pulmonary infiltrates
adverse reactions affecting the lung: possible association with D-penicillamine, suppl 166
Purpura
SLE and thrombotic thrombocytopenic purpura: a case report and review of relationship, 504
Pyoderma gangrenosum
avulsion of the quadriceps tendons in a patient with an unusual deforming arthritis and varied skin lesions, 983
Pyrithioxine
pyrithioxine and thiopronine: new penicillamine-like drug in RA, suppl 175
Pyrophosphate arthropathy
calcium pyrophosphate crystal formation in model hydrogels. II. hyaline articular cartilage as a gel, 451
cartilage matrix in hereditary pyrophosphate arthropathy, 959

Q

Quantitative immunofluorescence
a quantitative immunofluorescence assay for IgM rheumatoid factor, 837

R

RA *(see rheumatoid arthritis)*
Rabbit
^{99m}Tc-pertechnetate uptake measurement in the rabbit knee joint — I. Standardization of the method and measurements in experimental arthritis, 31
Radiographic evaluation
studies on the effect of D-penicillamine on type II collagen-induced polyarthritis, suppl 84
Rat
metabolism and pharmacokinetics of penicillamine in rats — an overview, suppl 35
Raynaud's phenomenon
Raynaud's phenomenon and initially seronegative MCTD, 632
Reactive arthritis
reactive arthritis associated with brucellosis: HLA studies, 621
Reiter's syndrome
cell-mediated immune responses of synovial mononuclear cells to sexually transmitted, enteric and mumps antigens in patients with Reiter's syndrome, RA and AS, 220
Reiter's syndrome following epidemic shigellosis, 969
the coexistence of RA with Reiter's syndrome and/or AS: a model of dual HLA-associated disease susceptibility and expression, 398
Relapsing polychondritis
relapsing polychondritis — pathogenic role of anti-native collagen type II antibodies: a case report with immunological and pathological studies, 820
Relationship
results of surgical treatment of nonambulatory rheumatoid patients, 328
Research
research is for now, too, *(editorial)* 361
Reticuloendothelial function
reticuloendothelial function in RA: correlation with disease activity and circulating immune complexes, 486
splenic reticuloendothelial function in patients with active RA, 490
Retroperitoneal fibrosis
the association of retroperitoneal fibrosis with systemic vasculitis and HLA-B27: a case report and review of the literature, 665
Review
an overview of assay methods for D-penicillamine, suppl 28
Rhabdomyosarcoma
monarticular arthritis: early manifestation of a rhabdomyosarcoma, 685
Rheumatic disease unit
costing: in search of a question, *(editorial)* 873
In memoriam, *(editorial)* 1
Rheumatic diseases
costing: in search of a question, *(editorial)* 873
regional rheumatology practice in Umea — a Northern Swedish experience, 110
the International League Against Rheumatism, *(editorial)* 705

Rheumatic fever
diagnosis of rheumatic fever obscured by liver disease, 138

Rheumatoid arthritis (RA)
a controlled study of group counseling in RA, 91
a double-blind comparison of high and low doses of levamisole in RA, 949
a study of the response of the leukopenia of RA to gold salt therapy, 658
annual fluctuations in RA, 725
antitrypsin activity and enzyme inhibitors in the rheumatoid joint, 547
autoantibody formation in D-penicillamine-treated RA, suppl 80
circulating immune complexes in patients with RA: correlation with disease activity, 851
coexistence of chronic tophaceous gout and RA, 989
coexistence of HLA-B27 AS and DR4 seropositive nodular RA in a patient with membranous nephropathy, 661
coexistence of RA in married couples: a search for etiological factors, 416
copper penicillaminate for RA, suppl 178
D-penicillamine-induced increase in intracellular glutathione correlating to clinical response in RA, suppl 14
differences of antigen composition of RA and non-RA derived tissue cultured synovial cells as detected by monkey anti-RA synovial cell sera, 204
effects of D-penicillamine on circulating protein complexes in RA and primary biliary cirrhosis, suppl 74
Felty's syndrome: case report and rationale for disease-suppressant immunosuppressive therapy, 791
Felty's syndrome: response to parenteral gold, 902
free-radical oxidation (peroxidation) products in serum and synovial fluid in RA, 233
gold in the treatment of Felty's syndrome, *(editorial)* 878
hematologic toxicity from penicillamine in RA, suppl 164
heterogeneity of HLA-DR4 in the RA of a Chippewa band, 797
hidden 19S IgM rheumatoid factor in synovial fluid, 811
HLA-DR4 in Negro and Mexican RA patients, 804
IgE rheumatoid factor in a case of RA with pleuritis, 299
immunobiology of D-penicillamine, suppl 56
incidence of atopy in rheumatic disease, 321
inosiplex: a novel treatment in RA?, 643
in vitro lymphocyte response in early RA, 468
lack of antibody in rheumatoid sera to autologous synovial macrophages and dendritic cells by antibody-dependent cellular cytotoxicity assays (ADCC), 647
levamisole – a possible alternative to gold and penicillamine in the longterm treatment of RA?, 730
levamisole as basic treatment of RA: longterm evaluation, 45
levamisole in RA: a comparison with D-penicillamine, 575
longterm follow-up of posterior cervical fusion for atlantoaxial subluxation in RA, 423
MCTD – a decade of growing pains, *(editorial)* 535
modulation of human antibody production *in vitro* by D-penicillamine and $CuSO_4$: inhibition of helper T cell function, suppl 69
multiple myeloma and amyloid bone lesions complicating RA, 845
myasthenia gravis and D-penicillamine, suppl 169
other penicillamine-like drugs, suppl 180
penicillamine in rheumatic diseases: a prospective study of tolerance and efficacy, suppl 107
penicillamine in the treatment of RA, suppl 103
peripheral hyperostosis in RA in the absence of axial involvement, 653
plasma exchange in RA, *(editorial)* 364
plasma exchange therapy for severe penicillamine-induced myasthenia gravis, 303
proteinuria in D-penicillamine-treated RA, suppl 161
pyrithioxine and thiopronine: new penicillamine-like drugs in RA, suppl 175
reticuloendothelial function in RA: correlation with disease activity and circulating immune complexes, 486
rheumatoid subcutaneous bursitis, 974
splenic reticuloendothelial function in patients with active RA, 490
superior margin rib defects in RA, 673
the coexistence of RA and SLE: a case report and review of the literature, 405
the coexistence of RA with Reiter's syndrome and/or AS: a model of dual HLA-associated disease susceptibility and expression, 398
the metabolism and pharmacology of D-penicillamine in man, suppl 41
the side effects of penicillamine therapy in RA, suppl 146
therapeutic strategy in RA: a roundtable discussion, suppl 124
uridine diphosphate glucose dehydrogenase in rheumatoid synovial cells in culture, 710

Rheumatoid factor
IgE rheumatoid factor in a case of RA with pleuritis, 299
phagocytosis and degradation of DNA-antiDNA complexes by human phagocytes. Influence of rheumatoid factors, 880
plasma exchange in rheumatoid vasculitis, 433
Rheumatoid nodules
the coexistence of RA and SLE: a case report and review of the literature, 405
Rheumatoid osteitis
histologic changes in rheumatoid disease of the metacarpal and metatarsal heads as seen in surgical material, 246
Rheumatoid vasculitis
plasma exchange in rheumatoid vasculitis, 433
Rheumatologist: population ratio
community rheumatology practice in Thunder Bay. A Canadian experience from Northwestern Ontario, 119
Rheumatology
regional rheumatology practice in Umea – a Northern Swedish experience, 110
research is for now, too, *(editorial)* 361
the growth of rheumatology, *(editorial)* 4
the International League Against Rheumatism, *(editorial)* 705
Rib defects
superior margin rib defects in RA, 673
Rice bodies
rice bodies in hypogammaglobulinemic arthritis, 165
RMP antibodies
MCTD – a decade of growing pains, *(editorial)* 535
Roundtable discussion
theraueptic strategy in RA: a roundtable discussion, suppl 124
Rye I grass antibodies
incidence of atopy in rheumatic disease, 321

S

Sacroiliitis arthritis
early diagnosis of septic arthritis of the sacroiliac joint by use of computed tomography, 979
osteomalacia, pseudosacroiliitis and necrosis of the femoral heads in Fanconi syndrome in an adult, 512
pyogenic sacroiliitis, 157
Sacroiliitis
the association of retroperitoneal fibrosis with systemic vasculitis and HLA-B27: a case report and review of the literature, 665
the musculoskeletal manifestations of acne fulminans, 317
Salmonella antigen
cell-mediated immune responses of synovial mononuclear cells to sexually transmitted, enteric and mumps antigens in patients with Reiter's syndrome, RA and AS, 220
Salmonella arthritis
cell-mediated immune responses of synovial mononuclear cells to sexually transmitted, enteric and mumps antigens in patients with Reiter's syndrome, RA and AS, 220
Salmonella infections
concurrent SLE and salmonellosis, 605
immune complexes in polyarthritis after salmonella gastroenteritis, 613
Salmonella polyarthritis
immune complexes in polyarthritis after salmonella gastroenteritis, 613
Sarcoid
sarcoidosis presenting as cutaneous ulceration, subcutaneous nodules and chronic arthritis, 311
Scleroderma
antigen-specific suppressor cell activity in patients with scleroderma, 747
eosinophilic fasciitis – new associations and current perspectives, *(editorial)* 6
MCTD – a decade of growing pains, *(editorial)* 535
PSS and penicillamine, suppl 116
SEAPAL
the International League Against Rheumatism, *(editorial)* 705
Sedimentation rate methodology
Whither Westergren – the sedimentation rate reevaluated, 331
Self-concept
a controlled study of group counseling in RA, 91
Septic arthritis
early diagnosis of septic arthritis of the sacroiliac joint by use of computed tomography, 979
patterns of gonococcal arthritis, *(editorial)* 707
pyogenic sacroiliitis. Diagnosis and significance, 153
Septic discitis
septic discitis, 100
Serum penicillamine
experience with penicillamine in the treatment of cystinuria, suppl 100
Shigellosis
Reiter's syndrome following epidemic shigellosis, 969
Sjögren's syndrome
chronic neutropenia: possible association with Sjögren's syndrome, 679
Skin toxicity
penicillamine-induced skin lesions, suppl 149

Skin windows
decreased numbers of monocytes in inflammatory exudates in SLE, 62
SLE *(see systemic lupus erythematosus)*
Splenic function
concurrent SLE and salmonellosis, 605
Spondyloarthropathy
Reiter's syndrome following epidemic shigellosis, 969
Still's disease
amyloidosis in adult onset Still's disease, 833
Streptokinase-streptodornase stimulation
in vitro lymphocyte response in early RA, 468
Stress fracture
stress fractures associated with adjacent OA, 161
Subclinical liver disease
subclinical liver disease in SLE, 752
Subcutaneous bursae
rheumatoid subcutaneous bursitis, 974
Superoxide dismutase
effects of oxygen-derived free radicals on connective tissue macromolecules: inhibition by copper-penicillamine complex, suppl 9
Superoxide radicals
oxy radicals and connective tissue, *(editorial)* 185
Suppressor cell dysfunction
suppressor T cell dysfunction and anti-suppressor cell antibody in active early RA, 9
Surgical treatment
results of surgical treatment of nonambulatory rheumatoid patients, 328
Survival
survival among patient with AS: a life-table analysis, 86
Symposium
abstracts, 1004
symposium on crystallography in the health sciences: crystalline deposits in human tissues, (introduction) 997
Synovial cells
lack of antibody in rheumatoid sera to autologous synovial macrophages and dendritic cells by antibody-dependent cellular cytotoxicity assays (ADCC), 647
rabbit synovial tissue in culture: influence of the inflammatory state *in vivo* on the secretion of collagenase, 367
Synovial effusions
free-radical oxidation (peroxidation) products in serum and synovial fluid in RA, 233
Synovial fluid
experimental joint trauma: synovial response to blunt trauma and inflammatory reaction to intraarticular injection of fat, 380
hidden 19S IgM rheumatoid factor in synovial fluid, 811
synovial fluid total hemolytic complement activity in rheumatic diseases – a reappraisal, 390
Synovial hyperplasia
experimental cholesterol crystal arthropathy, 281
Synovial lining cells
differences of antigen composition of RA and non-RA derived tissue cultured synovial cells as detected by monkey anti-RA synovial cell sera, 204
Synovial mononuclear cells
cell-mediated immune responses of synovial mononuclear cells to sexually transmitted, enteric and mumps antigens in patients with Reiter's syndrome, RA and AS, 220
Synovial tissue
uridine disphosphate glucose dehydrogenase in rheumatoid synovial cells in culture, 710
Synovium
experimental joint trauma: synovial response to blunt trauma and inflammatory reaction to intraarticular injection of fat, 380
Systemic lupus erythematosus (SLE)
bacterial monarthritis due to *Neisseria meningitidis* in SLE, 145
chronic interstitial cystitis as an initial major manifestation of SLE, 808
concurrent SLE and salmonellosis, 605
C-reactive protein in sera from patients with SLE, 599
C-reactive protein in the differential diagnosis between infection and disease reactivation in SLE, 291
decreased numbers of monocytes in inflammatory exudates in SLE, 62
genetic factors in SLE, 347
MCTD – a decade of growing pains, *(editorial)* 535
muscle disease in SLE: a study of its nature, frequency and cause, 917
non-Hodgkin's lymphoma in SLE. Report of 4 cases with ultrastructural studies in 2, 69
penicillamine and the SLE syndrome, suppl 155
sera from patients with SLE reactive with human endothelial cells, 581
SLE and thrombotic thrombocytopenic purpura: a case report and review of relationship, 504
SLE in a patient with C4 deficiency, 741
subclinical liver disease in SLE, 752
suppression of Fc receptor and C4.C3 receptors of the granulocytes from patients with SLE, 910
suppressor T cell dysfunction and depressed immunoglobulin production by B cells *in vitro* in patients with SLE, 19

T lymphocyte colony formation and autoimmune disease: *in vitro* assessment of immunopathology, 214
tendon rupture in SLE, 308
the coexistence of RA and SLE: a case report and review of the literature, 405
the potential role of immunoregulatory disturbance in the pathogenesis of SLE, 340
the potential role of microbial agents in the pathogenesis of SLE, 344
the side effects of penicillamine therapy in RA, suppl 146
the use of T cell subtyping to distinguish RA from SLE, 494

Systemic sclerosis
bowed fingers. A helpful sign in the early diagnosis of systemic sclerosis, 266

Systemic vasculitis
the association of retroperitoneal fibrosis with systemic vasculitis and HLA-B27: a case report and review of the literature, 665

T

T cell subtyping in RA
the use of T cell subtyping to distinguish RA from SLE, 494

T helper cells
D-penicillamine, lymphocytes, and macrophages: an account of experimental investigation *in vivo*, suppl 62

T lymphocytes
T lymphocyte colony formation and autoimmune disease: *in vitro* assessment of immunopathology, 214

Technetium-^{99m}
soft tissue uptake of bone seeking radionuclide in amyloidosis, 760

Tendon rupture
tendon rupture in SLE, 308

The Arthritis Society
In memoriam, *(editorial)* 1

The Journal of Rheumatology
the growth of rheumatology, *(editorial)* 4

The specialty of rheumatology
the growth of rheumatology, *(editorial)* 4

Therapeutic strategy
therapeutic strategy in RA: a roundtable discussion, suppl 124

Thiemann's disease
Thieman's disease, 462

Thioamide-induced lupus syndrome
familial thioamide-induced lupus syndrome in thyrotoxicosis, 498

Thiopronine
pyrithioxine and thiopronine: new penicillamine-like drugs in RA, suppl 175

Thrombocytopenia
hematologic toxicity from penicillamine in RA, suppl 164
the side effects of penicillamine therapy in RA, suppl 146

Thrombocytopenic
SLE and thrombotic thrombocytopenic purpura: a case report and review of relationship, 504

Thrombotic
SLE and thrombotic thrombocytopenic purpura: a case report and review of relationship, 504

Thyrotoxicosis
familial thioamide-induced lupus syndrome in thyrotoxicosis, 498

Trauma
experimental joint trauma: synovial response to blunt trauma and inflammatory reaction to intraarticular injection of fat, 380

Treatment
levamisole – a possible alternative to gold and penicillamine in the longterm treatment of RA?, 730

Treatment of RA
plasma exchange in RA, *(editorial)* 364

Type II collagen polyarthritis
studies on the effect of D-penicillamine on type II collagen-induced polyarthritis, suppl 84

Types of gonococcal arthritis
patterns of gonococcal arthritis, *(editorial)* 707

U

UDP-glucose dehydogenase
uridine diphosphate glucose dehydrogenase in rheumatoid synovial cells in culture, 710

Ulceration
sarcoidosis presenting as cutaneous ulceration, subcutaneous nodules and chronic arthritis, 311

Ultrastructure
cartilage matrix in hereditary pyrophosphate arthropathy, 959

Uptake measurement
^{99m}Tc-pertechnetate uptake measurement in the rabbit knee joint – I. Standardization of the method and measurements in experimental arthritis, 31

Utilization of care
regional rheumatology practice in Umea – a Northern Swedish experience, 110

V

Vasculitis-disease activity
correlation of disease activity in systemic necrotizing vasculitis with immune complexes, 258

W

Weber-Christian disease
factitial Weber-Christian disease: a case report, 129

Westergren sedimentation rate
Whither Westergren – the sedimentation rate reevaluated, 331

WHO
the International League Against Rheumatism, *(editorial)* 705

Wilson's disease
copper penicillaminate for RA, suppl 178
penicillamine and the SLE syndrome, suppl 155
the discovery of the therapeutic use of D-penicillamine, suppl 3
the metabolism and pharmacology of D-penicillamine in man, suppl 41
Wilson's disease, suppl 90

Y

Yersinia antigen
cell-mediated immune responses of synovial mononuclear cells to sexually transmitted, enteric and mumps antigens in patients with Reiter's syndrome, RA and AS, 220